ストックスクリーナーアプリを入手
1.73
0.57%
-0.01
アフターアワーズ：
1.70
-0.03
-1.73%
前日終値:
$1.74
開ける：
$1.74
24時間の取引高:
684.44K
Relative Volume:
0.14
時価総額：
$147.34M
収益：
-
当期純損益:
$-59.69M
株価収益率:
-1.2446
EPS:
-1.39
ネットキャッシュフロー:
$-46.54M
1週間 パフォーマンス:
+3.59%
1か月 パフォーマンス:
-12.63%
6か月 パフォーマンス:
+2.37%
1年 パフォーマンス:
-3.89%
1日の値動き範囲:
$1.72
$1.7747
1週間の範囲:
$1.61
$1.81
52週間の値動き範囲:
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
名前
Milestone Pharmaceuticals Inc
セクター
電話
(514) 336-0444
住所
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.73 | 148.19M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-15 | アップグレード | TD Cowen | Hold → Buy |
| 2025-09-11 | 開始されました | Wells Fargo | Overweight |
| 2025-06-05 | 再開されました | H.C. Wainwright | Buy |
| 2024-08-22 | 開始されました | Rodman & Renshaw | Buy |
| 2023-06-20 | ダウングレード | Jefferies | Buy → Hold |
| 2022-04-22 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-29 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-07-24 | アップグレード | Jefferies | Hold → Buy |
| 2020-03-25 | ダウングレード | Jefferies | Buy → Hold |
| 2020-03-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-03-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 開始されました | Oppenheimer | Outperform |
| 2019-06-03 | 開始されました | Cowen | Outperform |
| 2019-06-03 | 開始されました | Jefferies | Buy |
| 2019-06-03 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Milestone Pharmaceuticals Inc (MIST) 最新ニュース
Risk Recap: What is the long term forecast for Milestone Pharmaceuticals Inc stockJuly 2025 Sector Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
What is Milestone Pharmaceuticals Inc.’s book value per shareJuly 2025 Retail & Capital Efficient Trade Techniques - mfd.ru
Is Milestone Pharmaceuticals Inc.’s ROIC above industry average2025 Top Gainers & Safe Entry Trade Signal Reports - mfd.ru
Why Milestone Pharmaceuticals Inc. stock is a value investor pick2025 Bull vs Bear & Community Consensus Trade Signals - mfd.ru
Why analysts upgrade Milestone Pharmaceuticals Inc. stock2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Milestone Appoints David Sandoval as General Counsel - Intellectia AI
Will Milestone Pharmaceuticals Inc. stock split attract more investorsMarket Growth Report & Real-Time Buy Signal Notifications - mfd.ru
What is the long term forecast for Milestone Pharmaceuticals Inc. stock2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru
What are the risks of holding Milestone Pharmaceuticals Inc.July 2025 Summary & Risk Adjusted Buy and Sell Alerts - mfd.ru
Milestone Pharmaceuticals appoints David Sandoval as general counsel By Investing.com - Investing.com Australia
Milestone Pharmaceuticals appoints David Sandoval as general counsel - Investing.com Nigeria
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer - The Manila Times
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Milestone Pharmaceuticals (MIST) Awards New Equity Options - GuruFocus
Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule - TipRanks
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Published on: 2026-02-03 14:31:32 - baoquankhu1.vn
Market Review: Is Milestone Pharmaceuticals Inc a momentum stockJuly 2025 Recap & Daily Oversold Bounce Ideas - baoquankhu1.vn
Milestone Pharmaceuticals (NASDAQ:MIST) Insider David Bharucha Sells 12,245 Shares - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Insider Lorenz Muller Sells 11,180 Shares - MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells $124,273.12 in Stock - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells $66,629.39 in Stock - MarketBeat
Jeffrey Edward Nelson Sells 58,007 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock - MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells 58,007 Shares of Stock - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) CEO Joseph Oliveto Sells 133,054 Shares - MarketBeat
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy - Yahoo Finance
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - Finviz
Milestone Pharmaceuticals announces U.S. availability of cardamyst - Yahoo Finance
Milestone’s PSVT treatment CARDAMYST now available in US pharmacies By Investing.com - Investing.com Canada
Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies - TipRanks
Milestone Pharmaceuticals (MIST) Launches Cardamyst Nasal Spray in U.S. Market - GuruFocus
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - Taiwan News
Bull Run: Should I set a stop loss on Milestone Pharmaceuticals IncJuly 2025 Action & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Aug Fed Impact: Will Cohen Circle Acquisition Corp I outperform during market ralliesJuly 2025 Retail & Free Verified High Yield Trade Plans - baoquankhu1.vn
Insider Trends: Is Milestone Pharmaceuticals Inc undervalued by DCF analysisJuly 2025 Reactions & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Hedge Fund Bets: What is the long term forecast for Milestone Pharmaceuticals Inc stockM&A Rumor & Growth Focused Investment Plans - baoquankhu1.vn
Earnings Miss: Is Milestone Pharmaceuticals Incs ROIC above industry averageJuly 2025 Closing Moves & Growth Focused Stock Reports - baoquankhu1.vn
Aug Mood: Should I invest in Milestone Pharmaceuticals Inc before earningsCPI Data & Daily Profit Focused Screening - baoquankhu1.vn
US Stocks Recap: Is Milestone Pharmaceuticals Inc vulnerable to short sellers2025 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn
Swing Trade: How does Milestone Pharmaceuticals Inc compare to its peersWeekly Trend Summary & Long-Term Growth Plans - baoquankhu1.vn
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST) - Seeking Alpha
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ETF Watch: Will Milestone Pharmaceuticals Inc. stock gain from lower inflation2025 Institutional Moves & Technical Pattern Recognition Alerts - Bộ Nội Vụ
Milestone Pharmaceuticals Secures $75M Non-Dilutive Royalty Financing - TipRanks
Milestone Pharmaceuticals Completes Royalty Interest Sale - TradingView
Will Milestone Pharmaceuticals Inc. stock gain from lower inflationWeekly Trend Recap & Detailed Earnings Play Strategies - Улправда
Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Insider Sell: Joseph Oliveto Sells 43,500 Shares of Milestone Ph - GuruFocus
Joseph Oliveto Sells 43,000 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock - MarketBeat
Trend Report: Will Milestone Pharmaceuticals Inc stock gain from government policies2025 Volume Leaders & Safe Capital Growth Tips - Bộ Nội Vụ
Milestone Pharmaceuticals Inc (MIST) 財務データ
収益
当期純利益
現金流量
EPS
1.52%
1.68%
大文字化:
|
ボリューム (24 時間):